XHKG2170
Market cap105mUSD
Dec 27, Last price
2.88HKD
1D
6.67%
1Q
65.52%
Name
Suzhou Basecare Medical Co Ltd
Chart & Performance
Profile
Suzhou Basecare Medical Corporation Limited, an investment holding company, engages in the research, development, manufacture, and provision of genetic testing solutions for assisted reproduction and sale of genetic testing devices and instruments in the People's Republic of China. The company offers genetic test kit products, which include pre-implantation genetic test kits, such as PGT-A to detect aneuploidy; PGT-M to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also provides prenatal test kit products comprising CNV kits; postnatal test kit products consist of WES kits; and devices and instruments, including liquid nitrogen storage dewar, cryostorage system, automated workstation, sperm quality analyzer, and NGS sequencer. The company also engages in the research, development, manufacture, and sale of medical devices and instruments. In addition, it provides marketing services; and engages in the research and development of software for medical devices and instruments. The company serves hospitals and reproductive clinics. Suzhou Basecare Medical Corporation Limited was incorporated in 2010 and is headquartered in Suzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
Income | ||||||
Revenues | 207,976 47.60% | 140,901 31.32% | ||||
Cost of revenue | 455,492 | 362,641 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (247,516) | (221,740) | ||||
NOPBT Margin | ||||||
Operating Taxes | (2,970) | 6,013 | ||||
Tax Rate | ||||||
NOPAT | (244,546) | (227,753) | ||||
Net income | (191,685) 55.64% | (123,163) -14.26% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
Debt | ||||||
Debt current | 15,186 | 2,146 | ||||
Long-term debt | 278,516 | 75,540 | ||||
Deferred revenue | 2,520 | 380 | ||||
Other long-term liabilities | 380 | |||||
Net debt | (672,428) | (1,274,844) | ||||
Cash flow | ||||||
Cash from operating activities | (267,234) | (188,769) | ||||
CAPEX | (104,208) | (128,751) | ||||
Cash from investing activities | (324,814) | (88,698) | ||||
Cash from financing activities | 190,551 | 23,514 | ||||
FCF | (401,207) | (331,267) | ||||
Balance | ||||||
Cash | 945,712 | 1,332,146 | ||||
Long term investments | 20,418 | 20,384 | ||||
Excess cash | 955,731 | 1,345,485 | ||||
Stockholders' equity | (279,173) | (85,747) | ||||
Invested Capital | 1,961,716 | 1,749,081 | ||||
ROIC | ||||||
ROCE | ||||||
EV | ||||||
Common stock shares outstanding | 273,526 | 273,526 | ||||
Price | 2.35 -37.00% | 3.73 -43.05% | ||||
Market cap | 642,786 -37.00% | 1,020,252 -41.29% | ||||
EV | (30,712) | (255,862) | ||||
EBITDA | (227,949) | (213,353) | ||||
EV/EBITDA | 0.13 | 1.20 | ||||
Interest | 2,610 | 3,109 | ||||
Interest/NOPBT |